APA

Johnson S. A., Catovsky D., Child J. A., Newland A. C., Milligan D. W. & Janmohamed R. (19990413). Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. : Investigational new drugs.

Chicago

Johnson S A, Catovsky D, Child J A, Newland A C, Milligan D W and Janmohamed R. 19990413. Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. : Investigational new drugs.

Harvard

Johnson S. A., Catovsky D., Child J. A., Newland A. C., Milligan D. W. and Janmohamed R. (19990413). Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. : Investigational new drugs.

MLA

Johnson S A, Catovsky D, Child J A, Newland A C, Milligan D W and Janmohamed R. Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. : Investigational new drugs. 19990413.